Navigation Links
Reagan-Udall Foundation Announces New Board Chairman

WASHINGTON, July 15, 2014 /PRNewswire-USNewswire/ -- The Reagan-Udall Foundation for the FDA (RUF), an independent not-for-profit organization created by Congress for the purpose of advancing regulatory science critical to helping the U.S. Food and Drug Administration accomplish its mission, today announced that Mark C. Rogers, M.D., M.B.A., has been elected as Chairman of the RUF Board of Directors.

"It's an honor to welcome a physician, scientist, educator and executive as distinguished as Dr. Rogers to govern our Board," said Ellen V. Sigal, Ph.D., RUF Board Vice Chairman and Interim Board Chairman during the search. "Dr. Rogers brings with him decades of outstanding leadership in several fields of medicine and business. His experience and guidance will help to strengthen the Foundation's contribution to regulatory science."  Dr. Rogers succeeds Mark McClellan, M.D., Ph.D., the Board's founding Chairman, who continues to support the Foundation as a Board member leading the Innovation in Medical Evidence Development and Surveillance (IMEDS) program.

"It's a great privilege to be appointed Chair of this unique collaboration that has already contributed so much to advancing public health in just a few years," said Dr. Rogers. "I have great confidence that we'll continue to make important strides in accelerating regulatory science and ensuring FDA-regulated products that reach consumers continue to meet the highest standards of safety, efficacy and quality."

Following Dr. Rogers' appointment in 1977 as the first Director of the Pediatric Intensive Care Unit at The Johns Hopkins Hospital, he went on to be appointed Professor and Chair of the Department of Anesthesiology and Critical Care Medicine, then Associate Dean. He received his M.B.A. from the Wharton School of the University of Pennsylvania and, among other publications, authored what is now the international standard textbook in pediatric intensive care. Dr. Rogers has held several senior, pioneering leadership and foundational roles in biotechnology and biopharmaceutical companies and is involved in a number of public service activities.

The Reagan-Udall Foundation for the FDA is an independent 501(c)(3) not-for-profit organization created by Congress to advance the mission of the FDA by advancing regulatory science and research. With the ultimate goal of improving public health, the Foundation provides a unique opportunity to bring all parties to the table (FDA, patient groups, academia, other government entities and industry) to work together in a transparent way to create exciting new regulatory science.


SOURCE Reagan-Udall Foundation for the FDA
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America
3. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
4. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
7. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
8. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research
9. Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant
10. Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease
11. Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna ... announced today that the remaining 11,000 post-share consolidation ... Purchase Warrants (the "Series B Warrants") subject to ... exercised on November 23, 2015, which will result ... After giving effect to the issuance of such ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... are paramount. Insertion points for in-line sensors can represent a weak spot where ... InTrac 781/784 series of retractable sensor housings , which are designed to tolerate ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
Breaking Biology Technology:
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
Breaking Biology News(10 mins):